The estimated Net Worth of Robert D Mitchell is at least $1.68 Million dollars as of 19 May 2017. Robert Mitchell owns over 2,200 units of Endologix stock worth over $69,454 and over the last 20 years Robert sold ELGX stock worth over $1,612,453.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Robert Mitchell ELGX stock SEC Form 4 insiders trading
Robert has made over 8 trades of the Endologix stock since 2011, according to the Form 4 filled with the SEC. Most recently Robert bought 2,200 units of ELGX stock worth $9,504 on 19 May 2017.
The largest trade Robert's ever made was selling 45,000 units of Endologix stock on 7 April 2015 worth over $779,850. On average, Robert trades about 3,830 units every 69 days since 2004. As of 19 May 2017 Robert still owns at least 315,699 units of Endologix stock.
You can see the complete history of Robert Mitchell stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Robert Mitchell's mailing address?
Robert's mailing address filed with the SEC is 2, Musick, Irvine Spectrum, Irvine, Orange, California, 92618, United States of America.
Insiders trading at Endologix
Over the last 21 years, insiders at Endologix have traded over $72,068,611 worth of Endologix stock and bought 306,824 units worth $2,023,811 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott, and Capital Management Lp Camber. On average, Endologix executives and independent directors trade stock every 27 days with the average trade being worth of $13,088. The most recent stock trade was executed by Dan Lemaitre on 4 September 2020, trading 51,844 units of ELGX stock currently worth $2,592.
What does Endologix do?
Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, Nellix and Ovation. The company was founded in March 1992 and is headquartered in Irvine, CA.
What does Endologix's logo look like?
Complete history of Robert Mitchell stock trades at Align Technology, Angiodynamic Inc, and Endologix
Endologix executives and stock owners
Endologix executives and other stock owners filed with the SEC include:
-
Dan Lemaitre,
Director -
Leslie V Norwalk,
Director -
David M. Jennings,
VP-Human Resources -
Iii Thomas F Zenty,
Director -
Gregory D Waller,
Director -
Michael V. Chobotov,
Chief Technology Officer -
Amanda L. De Palma,
VP, Global Marketing -
John D Mc Dermott,
Chief Executive Officer -
Christopher G. Chavez,
Director -
James Edward Machek,
VP-Research & Development -
Shari L O'quinn,
VP, Clinical & Regulatory -
Thomas Wilder,
Director -
Guido J Neels,
Director -
Jose A. Lima,
VP-Quality -
Joseph A. De John,
General Manager, Asia & Pac -
Jeremy B. Hayden,
General Counsel -
Matthew Thompson,
Chief Medical Officer -
Laura Nagel,
VP, Quality -
Stefan Schreck,
Vice President -
Vaseem Mahboob,
Chief Financial Officer -
Jeffrey F Odonnell,
Director -
Capital Management Lp Camber,
-
International, L.P. Elliott,
10% owner -
Leonard M. Greenstein,
VP Finance & Corp Controller -
Greef Roderick De,
Director -
Robert D Mitchell,
President -
Martin Tyler,
V.P. Global Marketing -
Franklin D Brown,
Executive Chairman -
Woodlands Health Ventures F...,
10% owner -
Paul Mccormick,
Chief Executive Officer & Pres -
Associates, L.P. Elliott,
10% owner -
Edward Diethrich,
Director -
Daniel Hawkins,
Vice Pres - Global Marketing -
Todd Abraham,
VP of Operations -
Janet Mary Fauls,
Vice President RA/QA/QC -
Charles Steele Love,
VP-Clinical Affairs -
Shelley B Thunen,
Chief Financial Officer -
Cecile Ferracci,
General Manager, Europe -
Ronald H Coelyn,
Director -
John Onopchenko,
CEO and Director -
Karen Uyesugi,
Vice President -
Robert John Krist,
Chief Financial Officer -
Ruth Anne Lyons,
VP Global Marketing -
Gary I. Sorsher,
Vice President - Quality -
Joseph A Bishop,
Vice President Research & Devl -
Jeffrey H Thiel,
Director -
Maurice Buchbinder,
Director -
Herbert H Mertens,
Vice President of Sales/Mktg -
Michael R Henson,
Director -
David M Richards,
Chief Financial Officer & Secr -
John Zehren,
Chief Commercial Officer -
Jeff Fecho,
Chief Quality Officer -
Jane E Kiernan,
Director -
Cynthia Buch Pinto,
Interim CFO -
Timothy Nicholas Brady,
Controller and Corp Secretary